CXCL10 and central nervous system cancer: Antibody-mediated blockade of CXCR3, CXCL10’s cognate receptor, also reduces CD8+ T cell chemotaxis toward the supernatant of CXCL10-containing IDH1-WT glioma cells by roughly 3.5-fold (93).